We cannot underestimate how potentially powerful these initial PILLAR results can have on this company. If the rest of the study have the same results, the medical community is going to be hard pressed to not insist that Pinpoint become a standard of care for at least laparoscopic left colectomies. Standard of care means either use Pinpoint for this procedure or run the risk of being sued in the event of leakage. That's a pretty powerful motivator for hospitals. It is that possibility that I believe is driving the stock as hard as it is today.